Wednesday, May 26, 2021 8:34:51 PM
Here is the key phrase...
Appearances can often be ephemeral and only made that much more so when showing a false correlation, as does that of Elite's share price, vis-a-vis, profitability v. not.
Many times, research reveals a trend or a connection between two things. Sometimes, that trend or connection is meaningful and other times it is not. In order to be able to tell the difference between a false correlation and a matter of cause-and-effect, someone engaging in critical thinking must fall back on the scientific method and look for causality (remember, I just talked about that).
For example, while there is a correlation between the numbers offered, there is no causation. In neither case, as the evidence provided makes clear, is the share price caused by Elite's profitability or non-profitability. However, while the profitability of a company and its valuation are highly correlated statistically, it is important to note that the valuation is based on business fundamentals and not the share price.
The bottom line...the share price may be correlated to the valuation of a firm...but it is not the cause of its valuation. The cause of the valuation of Elite is its business fundamentals/financials as seen in its debt and equity ratios, not the share price.
I hope this clears up the confusion.
It appears...
Appearances can often be ephemeral and only made that much more so when showing a false correlation, as does that of Elite's share price, vis-a-vis, profitability v. not.
Many times, research reveals a trend or a connection between two things. Sometimes, that trend or connection is meaningful and other times it is not. In order to be able to tell the difference between a false correlation and a matter of cause-and-effect, someone engaging in critical thinking must fall back on the scientific method and look for causality (remember, I just talked about that).
For example, while there is a correlation between the numbers offered, there is no causation. In neither case, as the evidence provided makes clear, is the share price caused by Elite's profitability or non-profitability. However, while the profitability of a company and its valuation are highly correlated statistically, it is important to note that the valuation is based on business fundamentals and not the share price.
The bottom line...the share price may be correlated to the valuation of a firm...but it is not the cause of its valuation. The cause of the valuation of Elite is its business fundamentals/financials as seen in its debt and equity ratios, not the share price.
I hope this clears up the confusion.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
